- Home
- JHX vs EXEL Comparison
JHX vs EXEL Comparison
Compare JHX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHX
- EXEL
- Stock Information
- Founded
- JHX 1888
- EXEL 1994
- Country
- JHX Ireland
- EXEL United States
- Employees
- JHX N/A
- EXEL N/A
- Industry
- JHX Building Materials
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JHX Industrials
- EXEL Health Care
- Exchange
- JHX Nasdaq
- EXEL Nasdaq
- Market Cap
- JHX 11.8B
- EXEL 10.4B
- IPO Year
- JHX N/A
- EXEL 2000
- Fundamental
- Price
- JHX $17.39
- EXEL $40.81
- Analyst Decision
- JHX Strong Buy
- EXEL Buy
- Analyst Count
- JHX 9
- EXEL 24
- Target Price
- JHX $28.00
- EXEL $44.73
- AVG Volume (30 Days)
- JHX 5.8M
- EXEL 3.2M
- Earning Date
- JHX 11-18-2025
- EXEL 11-04-2025
- Dividend Yield
- JHX N/A
- EXEL N/A
- EPS Growth
- JHX N/A
- EXEL 53.55
- EPS
- JHX 0.77
- EXEL 2.38
- Revenue
- JHX $3,785,500,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- JHX $21.70
- EXEL $9.14
- Revenue Next Year
- JHX $16.85
- EXEL $12.51
- P/E Ratio
- JHX $29.58
- EXEL $17.17
- Revenue Growth
- JHX N/A
- EXEL 9.93
- 52 Week Low
- JHX $16.64
- EXEL $31.90
- 52 Week High
- JHX $37.65
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- JHX 26.09
- EXEL 58.21
- Support Level
- JHX $21.47
- EXEL $36.00
- Resistance Level
- JHX $22.49
- EXEL $41.55
- Average True Range (ATR)
- JHX 0.65
- EXEL 1.39
- MACD
- JHX -0.54
- EXEL 0.27
- Stochastic Oscillator
- JHX 11.03
- EXEL 87.63
About JHX James Hardie Industries plc (Ireland)
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Following the Azek acquisition in 2025, it also produces wooden composite decking materials, siding trims, and accessories for outdoor areas including stair and deck railing. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.